Agile Therapeutics Inc (AGRX) Sees Significant Increase in Short Interest

Agile Therapeutics Inc (NASDAQ:AGRX) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,529,877 shares, an increase of 124.2% from the October 15th total of 1,128,282 shares. Currently, 10.6% of the company’s shares are sold short. Based on an average daily volume of 4,351,706 shares, the short-interest ratio is presently 0.6 days.

Agile Therapeutics stock opened at $1.00 on Friday. Agile Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $5.33. The company has a market cap of $33.08 million, a PE ratio of -1.10 and a beta of -0.95.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. On average, sell-side analysts expect that Agile Therapeutics will post -0.6 EPS for the current fiscal year.

AGRX has been the subject of several analyst reports. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. HC Wainwright set a $4.00 price objective on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $4.00.

Several institutional investors have recently bought and sold shares of the company. Fosun International Ltd bought a new stake in shares of Agile Therapeutics during the third quarter valued at approximately $180,000. Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 76.3% during the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 343,290 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares in the last quarter. 51.92% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: Index Funds

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply